Sartorius (SRT) AI Stock Analysis

Compare

27 Followers

Top Page

Sartorius

(XETRA:SRT)

Rating:63Neutral

Price Target:

€173.00

▲(7.86% Upside)

Sartorius's overall stock score is driven by strong operational efficiency and positive earnings call sentiment, highlighting growth in consumables and profitability. However, high leverage, declining free cash flow, and overvaluation concerns weigh down the score. Technical indicators suggest a bearish trend, further impacting the stock's attractiveness.

Sartorius (SRT) vs. iShares MSCI Germany ETF (EWG)

Market Cap

€12.34B

Dividend Yield0.46%

Average Volume (3M)5.77K

Price to Earnings (P/E)106.4

Beta (1Y)1.57

Revenue Growth3.80%

EPS Growth33.31%

CountryDE

Employees13,573

SectorHealthcare

Sector Strength45

IndustryMedical - Instruments & Supplies

Share Statistics

EPS (TTM)1.22

Shares Outstanding37,440,000

10 Day Avg. Volume3,298

30 Day Avg. Volume5,771

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€223.25

Price Target Upside39.18% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Sartorius Business Overview & Revenue Model

Company DescriptionSartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

How the Company Makes MoneySartorius generates revenue primarily through the sale of its bioprocessing and laboratory products, which includes instruments, consumables, and services. The Bioprocess Solutions segment is a significant revenue driver, providing equipment and technologies that facilitate the production of biopharmaceuticals. The Lab Products & Services segment contributes by offering laboratory instruments and consumables, as well as support and maintenance services. Key revenue streams include direct sales to customers, long-term service agreements, and recurring revenues from consumables used in bioprocessing. Sartorius also benefits from strategic partnerships with pharmaceutical companies and research organizations, enhancing its market reach and fostering innovation in product development.

Sartorius Earnings Call Summary

Earnings Call Date:Jul 22, 2025

(Q2-2025)

% Change Since: |

Next Earnings Date:Oct 16, 2025

Earnings Call Sentiment Positive

The earnings call reflected a positive sentiment with strong growth in consumables and increased profitability. However, challenges in the equipment business and tariff impacts were noted, indicating a cautious outlook for the second half of the year.

Q2-2025 Updates

Positive Updates

Strong Revenue Growth

Sartorius reported a revenue growth of 6% in constant currencies, driven by a strong increase in consumables sales. The Bioprocessing Solutions sales revenue grew by nearly 9% year-over-year on a constant currency basis.

Increased Profitability

The underlying EBITDA increased by 12% year-over-year, with the EBITDA margin approaching 30%. This margin expansion was driven by positive volume, product mix, and economies of scale.

Launch of New Products

Introduced new products in both bioprocessing and lab divisions, including a platform for incentivized bioprocesses and the new model of IncuCyte for real-time cell observation.

Confirmation of Full-Year Guidance

The company confirmed its full-year 2025 guidance, indicating confidence in meeting revenue and EBITDA margin targets.

Negative Updates

Soft Equipment Business

The equipment business remains soft, with continued hesitation around larger capital investments by customers, leading to a decline in sales revenue for the Lab Products & Services division by 4% in constant currency.

Tariff Challenges

Began facing tariff challenges starting April 2, with anticipated effects expected to increase over the second half of the year.

LPS Instrument Demand Lagging

Demand for Lab Products & Services instruments continues to lag expectations, contributing to the overall decline in the division's performance.

Company Guidance

During the H1 2025 conference call for Sartorius and Sartorius Stedim Biotech, the company provided several key financial metrics and guidance. Sartorius reported a 6% growth in revenue in constant currencies, with the underlying EBITDA increasing by 12% year-over-year, resulting in an EBITDA margin nearing 30%. Bioprocessing Solutions revenue grew by nearly 9% year-over-year, while Lab Products & Services saw a 4% decline in constant currency sales. The company confirmed its full-year 2025 guidance, projecting a 6% increase in constant currencies for the group, with EBITDA margins expected between 29% and 30%. Sartorius also highlighted its continued focus on innovation, mentioning new product launches and the completion of the MatTek acquisition, which will contribute to the financial results in the second half of the year. Despite uncertainties, Sartorius expressed confidence in meeting its full-year targets, supported by strong consumables demand and strategic investments in capacity and technology.

Sartorius Financial Statement Overview

Summary

Sartorius demonstrates strong operational efficiency with solid gross and EBIT margins. However, the company faces challenges with high leverage and declining free cash flow, which could impact financial stability. Despite these challenges, the company maintains a strong market position in the medical instruments industry.

Income Statement

Positive

Sartorius shows a strong gross profit margin of 45.76% in TTM, indicating efficient production and pricing strategies. However, the net profit margin is relatively low at 3.86%, suggesting high operational costs or other expenses. Revenue growth has been inconsistent, with a notable decline in 2023 but a recovery in TTM. EBIT and EBITDA margins are healthy, reflecting good operational efficiency.

Balance Sheet

Positive

The company has a high debt-to-equity ratio of 1.75 in TTM, indicating significant leverage, which could pose financial risks. Return on equity has decreased over the years, standing at 4.95% in TTM, reflecting lower profitability for shareholders. The equity ratio is moderate, suggesting a balanced asset financing approach.

Cash Flow

Positive

Operating cash flow is robust, but free cash flow has declined by 16.30% in TTM, indicating potential challenges in cash generation. The operating cash flow to net income ratio is healthy, suggesting good cash conversion. However, the free cash flow to net income ratio indicates some pressure on cash flow relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.47B	3.38B	3.40B	4.17B	3.45B	2.34B
Gross Profit	1.59B	1.52B	1.57B	2.20B	1.84B	1.21B
EBITDA	860.00M	786.80M	873.10M	1.54B	945.12M	662.13M
Net Income	133.70M	84.00M	205.20M	913.10M	426.98M	321.47M
Balance Sheet
Total Assets	10.03B	10.10B	9.76B	6.98B	5.70B	4.70B
Cash, Cash Equivalents and Short-Term Investments	871.80M	828.70M	394.20M	196.80M	360.99M	217.65M
Total Debt	4.66B	4.56B	5.31B	2.54B	2.08B	2.09B
Total Liabilities	6.23B	6.21B	7.00B	4.32B	3.98B	3.30B
Stockholders Equity	2.66B	2.76B	2.07B	1.99B	1.26B	1.05B
Cash Flow
Free Cash Flow	575.30M	566.30M	293.90M	211.60M	458.65M	271.27M
Operating Cash Flow	918.80M	976.20M	853.60M	734.20M	865.81M	511.52M
Investing Cash Flow	-354.40M	-425.80M	-2.82B	-1.13B	-569.61M	-1.27B
Financing Cash Flow	-344.00M	-128.30M	2.17B	209.90M	-165.18M	907.47M

Sartorius Technical Analysis

Technical Analysis Sentiment

Negative

Last Price160.40

Price Trends

50DMA

165.48

Negative

100DMA

170.10

Negative

200DMA

177.87

Negative

Market Momentum

MACD

-0.57

Negative

RSI

49.80

Neutral

STOCH

45.69

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SRT, the sentiment is Negative. The current price of 160.4 is above the 20-day moving average (MA) of 156.48, below the 50-day MA of 165.48, and below the 200-day MA of 177.87, indicating a neutral trend. The MACD of -0.57 indicates Negative momentum. The RSI at 49.80 is Neutral, neither overbought nor oversold. The STOCH value of 45.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:SRT.

Sartorius Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRT	63 Neutral	€12.34B	106.38	3.88%	0.46%	3.80%	33.31%
Sector *	51 Neutral	$7.83B	-0.15	-40.10%	2.29%	21.46%	-2.01%
0DHC	―	€3.84B	24.30	7.48%	―	―	―
0H9X	―	€12.81B	19.50	4.83%	―	―	―
0OO9	―	€26.38B	23.88	7.30%	―	―	―
0O14	―	€47.83B	17.03	10.08%	―	―	―
SEMHF	―	$61.32B	26.39	11.75%	1.77%	―	―

* Healthcare Sector Average

Performance Comparison

DE:SRT

Sartorius

160.40

-31.39

-16.37%

GB:0DHC

Carl Zeiss Meditec

43.34

-21.93

-33.60%

GB:0H9X

Fresenius Medical Care AG & Co. KGaA

43.66

9.46

27.66%

GB:0OO9

Fresenius SE & Co. KGaA

47.02

14.47

44.45%

GB:0O14

Merck KGaA

109.00

-61.73

-36.16%

SEMHF

Siemens Healthineers AG

53.90

-2.84

-5.01%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 20, 2025